Kymera Therapeutics, Inc. Common Stock (KYMR) is a publicly traded Healthcare sector company. As of May 21, 2026, KYMR trades at $80.28 with a market cap of $6.55B and a P/E ratio of -21.86. KYMR moved +3.33% today. Year to date, KYMR is +11.38%; over the trailing twelve months it is +156.52%. Its 52-week range spans $19.45 to $103.00. Analyst consensus is strong buy with an average price target of $119.07. Rallies surfaces KYMR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kymera climbs as Fast Track KT-621 momentum and May conference catalysts fuel bid: Kymera Therapeutics shares rose as investors continued to price in its April 30, 2026 Q1 update highlighting new FDA Fast Track designation for KT-621 in moderate-to-severe eosinophilic asthma and multiple near-term medical-meeting presentations in May. The company also reported $34.4 million in Q1 2026 collaboration revenue and ended March 31, 2026 with $1.55 billion in cash and marketable securities.
| Metric | Value |
|---|---|
| Price | $80.28 |
| Market Cap | $6.55B |
| P/E Ratio | -21.86 |
| EPS | $-3.69 |
| Dividend Yield | 0.00% |
| 52-Week High | $103.00 |
| 52-Week Low | $19.45 |
| Volume | 321 |
| Avg Volume | 0 |
| Revenue (TTM) | $39.21M |
| Net Income | $-311.35M |
| Gross Margin | 0.00% |
16 analysts cover KYMR: 0 strong buy, 16 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $119.07.